| Document Date: 2012-09-04 07:00:22
Open Document File Size: 286,47 KBShare Result on Facebook
City Princeton / Horsham / Greenwood / Osnago / Flawil / Worcestershire / / Company Novartis Pharmaceuticals / Jean C. Sung Pulmatrix Inc. / Gilead Pharmaceuticals / Shoyele S.A. / BÜCHI Labortechnik AG / Plastiape S.p.A. / / Country Switzerland / United States / Italy / United Kingdom / / Event FDA Phase / / Facility American College of Chest Physicians / / IndustryTerm target site / inhalation solution / dry powder drug delivery technology / iSPERSE technology / / MedicalCondition Pseudomonas / PA infection / PA lung infection / pulmonary infections / inflammatory cytokine levels / antibiotic / cystic fibrosis / persistent infection / longterm pulmonary complications / Pseudomonas aeruginosa / INTRODUCTION Progressive obstructive lung disease / cystic fibrosis / chronic pulmonary infections / / MedicalTreatment drug delivery system / antibiotics / alternative therapy / alternative therapies / / Organization American College of Chest Physicians / / Person Michael M. Lipp / Robert W. Clarke / Diana Manzanedo / Steven R. Kramer / Microbiology / Wesley H. DeHaan / Matthew Brande / / Position representative / / Product Levofloxacin / TOBI / SC / sodium chloride / tobramycin / United States / / PublishedMedium Current Opinion / Antimicrobial Agents and Chemotherapy / / Technology Pharmacokinetics / dry powder drug delivery technology / laser / Drug Delivery / biopharmaceuticals / Drug Delivery Technology / iSPERSE technology / Biotechnology / Chemotherapy / drug delivery system / CONCLUSIONS The iSPERSE technology / /
SocialTag |
Formulation Characterization of a Novel Levofloxacin Pulmonary Dry Powder Drug Delivery Technology